Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat

Metabolism: Clinical and Experimental

Volumn 48, Issue 10, 1999, Pages 1248-1255

  Nawano, Masao ^b   Anai, Motonobu ^b   Funaki, Makoto ^b   Kobayashi, Hiroyuki ^b   Kanda, Akira ^b   Fukushima, Yasushi ^b   Inukai, Kouichi ^b   Ogihara, Takehide ^b   Sakoda, Hideyuki ^b   Onishi, Yukiko ^b   Kikuchi, Masatoshi ^b   Yazaki, Yoshio ^b   Oka, Yoshitomo ^b   Asano, Tomoichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; IMIDAPRIL; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; PHOSPHATIDYLINOSITOL 3 KINASE; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSURIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRADUODENAL DRUG ADMINISTRATION; LIVER BLOOD FLOW; MUSCLE BLOOD FLOW; NONHUMAN; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE;

EID: 13044280784     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(99)90263-9     Document Type: Article

References (56)

1. Sawicki PT, Berger M: Pharmacological treatment of diabetic patients with cardiovascular complications. J Intern Med 243:181-189, 1998
2. Makrilakis K, Bakris G: Diabetic hypertensive patients: Improving their prognosis. J Cardiovasc Pharmacol 31:S34-S40, 1998 (suppl 2)
3. Clark CM Jr, Lee DA: Prevention and treatment of the complications of diabetes mellitus. N Engl J Med 332:1210-1217, 1995
4. Huang XH, Rantalaiho V, Wirta O, et al: Relationship of the angiotensin-converting enzyme gene polymorphism to glucose intolerance, insulin resistance, and hypertension in NIDDM. Hum Genet 102:372-378, 1998
5. Lithell HO: Insulin resistance as an intermediary endpoint. Blood Press Suppl 2:108-112, 1997
6. Lachaal M, Jung CY: Insulin resistance and hypertension. Mol Cell Biochem 109:119-125, 1992
7. Passa P: Hyperinsulinemia, insulin resistance and essential hypertension. Horm Res 38:33-38, 1992
8. Akuzawa N, Nakamura T, Kurashina T, et al: Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis. Am J Hypertens 11:697-707, 1998
9. Donnelly R, Molyneaux LM, Willey KA, et al: Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria. Am J Cardiol 77:26B-30B, 1996
10. Brown NJ, Vaughan DE: Angiotensin-converting enzyme inhibitors. Circulation 97:1411-1420, 1998
11. Ruschitzka FT, Noll G, Luscher TF: Combination of ACE inhibitors and calcium antagonists. J Cardiovasc Pharmacol 31:S5-S16, 1998 (suppl 2)
12. Weissberg PL: Mechanisms of vascular smooth muscle cell proliferation. Ann Acad Med Singapore 20:38-42, 1991
13. Paolisso G, Gambardella A, Verza M, et al: ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens 6:175-179, 1992
14. Alonso-Galicia M, Brands MW, Zappe DH, et al: Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 28:1047-1054, 1996
15. Henriksen EJ, Jacob S, Augustin HJ, et al: Glucose transport activity in insulin-resistant rat muscle: Effects of angiotensinconverting enzyme inhibitors and bradykinin antagonism. Diabetes 45:S125-S128, 1996(suppl 1)
16. Kirchengast M: Preclinical considerations and results with the combination of verapamil and trandolapril: Blood pressure reduction and beyond. J Hypertens Suppl 15:S27-S33, 1997
17. Henriksen EJ, Jacob S: Effects of captopril on glucose transport activity in skeletal muscle of obese Zucker rats. Metabolism 44:267-272, 1995
18. Berne C: Metabolic effects of ACE inhibitors. J Intern Med Suppl 735:119-125, 1991
19. Velloso LA, Folli F, Sun XJ, et al: Cross-talk between the insulin and angiotensin signaling systems. Proc Natl Acad Sci USA 93:12490-12495, 1996
20. Anai M, Funaki M, Ogihara T, et al: Altered expression levels and impaired steps in the pathway to phosphatidylinositol 3-kinase activation via insulin receptor substrates 1 and 2 in Zucker fatty rats. Diabetes 47:13-23, 1998
21. Erni D, Banic A, Wheatley AM, et al: Haemorrhage during anaesthesia and surgery: Continuous measurement of microcirculatory blood flow in the kidney, liver, skin and skeletal muscle. Eur J Anaesthesiol 12:423-429, 1995
22. Hallakou S, Doare L, Foufelle F, et al: Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46:1393-1399, 1997
23. Terasaki J, Anai M, Funaki M, et al: Role of JTT-501, a new insulin sensitiser, in restoring impaired GLUT4 translocation in adipocytes of rats fed a high fat diet. Diabetologia 41:400-409, 1998
24. Kono T: Recycling of insulin-sensitive glucose transporter in rat adipocytes. Methods Enzymol 98:431-444, 1983
25. Simpson IA, Cushman SW: Hormonal regulation of mammalian glucose transport. Annu Rev Biochem 55:1059-1089, 1986
26. Oka Y, Czech MP: Photoaffinity labeling of insulin-sensitive hexose transporters in intact rat adipocytes. Direct evidence that latent transporters become exposed to the extracellular space in response to insulin. J Biol Chem 259:8125-8133, 1984
27. Katagiri H, Asano T, Ishihara H, et al: Overexpression of catalytic subunit p110alpha of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1 adipocytes. J Biol Chem 271:16987-16990, 1996
28. Kotani K, Carozzi AJ, Sakaue H, et al: Requirement for phosphoinositide 3-kinase in insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytes. Biochem Biophys Res Commun 209:343-348, 1995
29. Quon MJ, Chen H, Ing BL, et al: Roles of 1-phosphatidylinositol 3-kinase and rats in regulating translocation of GLUT4 in transfected rat adipose cells. Mol Cell Biol 15:5403-5411, 1995
30. Okada T, Kawano Y, Sakakibara T, et al: Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J Biol Chem 269:3568-3573, 1994
31. Cheatham B, Vlahos CJ, Cheatham L, et al: Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 14:4902-4911, 1944
32. Haruta T, Morris AJ, Rose DW, et al: Insulin-stimulated GLUT4 translocation is mediated by a divergent intracellular signaling pathway. J Biol Chem 270:27991-27994, 1995
33. Krook A, Kawano Y, Song XM, et al: Improved glucose tolerance restores insulin-stimulated Akt kinase activity and glucose transport in skeletal muscle from diabetic Goto-Kakizaki rats. Diabetes 46:2110-2114, 1997
34. Alessi DR, Cohen P: Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 8:55-62, 1998
35. Gabbay RA, Sutherland C, Gnudi L, et al: Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras/mitogen-activated protein kinase signaling path-way. J Biol Chem 271:1890-1897, 1996
36. Daly ME, Vale C, Walker M, et ai: Dietary carbohydrates and insulin sensitivity: A review of the evidence and clinical implications. Am J Clin Nutr 66:1072-1085, 1997
37. Elson DF, Meredith M: Therapy for type 2 diabetes mellitus. Wis Med J 97:49-54,1998
38. Kaplan NM: Obesity in hypertension: Effects on prognosis and treatment. J Hypertens Suppl 16:S35-S37, 1998
39. Goodyear LJ, Kahn BB: Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 49:235-261, 1998
40. Saad MJ, Folli F, Kahn JA, et al: Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 92:2065-2072, 1993
41. Folli F, Saad MJ, Backer JM, et al: Regulation of phosphatidylinositol 3-kinase activity in liver and muscle of animal models of insulin-resistant and insulin-deficient diabetes mellitus. J Clin Invest 92:1787-1794, 1993
42. Goodyear L, Giorgino F, Sherman LA, et al: Insulin receptor phosphorylation, insulin receptor substrate-1, phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 95:2195-2204, 1995
43. Zierath JR, He L, Guma A, et al: Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 39:1180-1189, 1996
44. Kobayashi M, Iwanishi M, Egawa K, et al: Pioglitazone increases insulin sensitivity by activating insulin receptor kinase. Diabetes 41:476-483, 1992
45. Sizer KM, Smith CL, Jacob CS, et al: Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism. Mol Cell Endocrinol 102:119-129, 1994
46. Zhang B, Szalkowski D, Diaz E, et al: Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedionederived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptors and L6 myotubes. J Biol Chem 269:25735-25741, 1994
47. Iwanishi M, Kobayashi M: Effect of pioglitazone on insulin receptors of skeletal muscles from high-fat-fed rats. Metabolism 42:1017-1021, 1993
48. Carvalho CR, Thirone AC, Gontijo JA, et al: Effect of captopril, losartan, and bradykinin on early steps of insulin action. Diabetes 46:1950-1957, 1997
49. Sawka-Verheile D, Tartare-Deckert S, White MF, et al: Insulin receptor substrate-2 binds to the insulin receptor through its phosphotyrosine-binding domain and through a newly identified domain compris-ing amino acids 591-786. J Biol Chem 271:5980-5983, 1996
50. He W, Craparo A, Zhu Y, et al: Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors. Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2. J Biol Chem 271:11641-11648, 1996
51. Ogihara T, Shin BC, Anai M, et al: Insulin receptor substrate (IRS)-2 is dephosphorylated more rapidly than IRS-1 via its association with phosphatidylinositol 3-kinase in skeletal muscle cells. J Biol Chem 272:12868-12873, 1997
52. Inoue G, Cheatham B, Emkey R, et al: Dynamics of insulin signaling in 3T3-L1 adipocytes. Differential compartmentalization and trafficking of insulin receptor substrate (IRS)-1 and IRS-2. J Biol Chem 273:11548-11555, 1998
53. Rother KI, Imai Y, Caruso M, et al: Evidence that IRS-2 phosphorylation is required for insulin action in hepatocytes. J Biol Chem 273:17491-17497, 1998
54. Uehara M, Kishikawa H, Isami S, et al: Effect on insulin sensitivity of angiotensin converting enzyme inhibitors with or without a sulphydryl group: Bradykinin may improve insulin resistance in dogs and humans. Diabetologia 37:300-307, 1994
55. Hirooka Y, Imaizumi T, Masaki H, et al: Captopril improves impaired endothelium-dependent vasodilation in hypertensive patients. Hypertension 20:175-180, 1992
56. Kodama J, Katayama S, Tanaka K, et al: Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care 13:1109-1111, 1990